GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kymera Therapeutics Inc (NAS:KYMR) » Definitions » Other Current Assets

Kymera Therapeutics (Kymera Therapeutics) Other Current Assets : $14.68 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kymera Therapeutics Other Current Assets?

Kymera Therapeutics's other current assets for the quarter that ended in Mar. 2024 was $14.68 Mil.

Kymera Therapeutics's quarterly other current assets declined from Sep. 2023 ($14.09 Mil) to Dec. 2023 ($11.67 Mil) but then increased from Dec. 2023 ($11.67 Mil) to Mar. 2024 ($14.68Mil).

Kymera Therapeutics's annual other current assets increased from Dec. 2021 ($8.72 Mil) to Dec. 2022 ($9.71 Mil) increased from Dec. 2022 ($9.71 Mil) to Dec. 2023 ($11.67 Mil).


Kymera Therapeutics Other Current Assets Historical Data

The historical data trend for Kymera Therapeutics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kymera Therapeutics Other Current Assets Chart

Kymera Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial 0.89 4.70 8.72 9.71 11.67

Kymera Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.35 13.71 14.09 11.67 14.68

Kymera Therapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Kymera Therapeutics Other Current Assets Related Terms

Thank you for viewing the detailed overview of Kymera Therapeutics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Kymera Therapeutics (Kymera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 Arsenal Yards Boulevard, Suite 230, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Executives
Jeffrey W. Albers director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Ellen Chiniara officer: Chief Legal Officer 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jeremy G Chadwick officer: Chief Operating Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
Bruce N. Jacobs officer: Chief Financial Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Leigh Morgan director KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
John Maraganore director 75 SIDNEY ST, CAMBRIDGE MA 02139
Nello Mainolfi director, officer: President and CEO C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Jared Gollob officer: Chief Medical Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Richard Chesworth officer: Chief Scientific Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Atlas Venture Associates X, L.p. 10 percent owner 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Elaine Caughey officer: Chief Business Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472

Kymera Therapeutics (Kymera Therapeutics) Headlines

From GuruFocus

Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

By Stock market mentor Stock market mentor 01-04-2023